Neoadjuvant Anti-CTLA4 Blockade With Ipilimumab in Patients With AJCC Stage IIIB-C (Tx,1-4, N1b,2b, 2c, 3, M0) Melanoma: Immunogenicity And Biomarker Analysis
Phase of Trial: Phase 0
Latest Information Update: 11 Dec 2017
At a glance
- Drugs Ipilimumab (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- 05 Dec 2017 Status changed from active, no longer recruiting to completed.
- 26 Jul 2017 Planned End Date changed from 1 Dec 2016 to 1 Nov 2017.
- 26 Jul 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Nov 2017.